Condition: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma · Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer · Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer · Sponsor: Auricula Biosciences Inc.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
This description comes directly from the study's public registry record.
Michele Finn, MSc · 1-438-884-9551 · inquiries@auriculabiosciences.com
Always discuss trial participation with your own doctor first.
| NEXT Oncology Dallas | Dallas, Texas, United States | Recruiting |
| Next Oncology, San Antonio | San Antonio, Texas, United States | Recruiting |
| Princess Margareth Cancer Center | Toronto, Ontario, Canada | Recruiting |
| Oxford University Hospital | Headington, Oxford, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07148128